Shaily Engineering is a company that specializes in precision manufacturing, with a particular focus on the healthcare segment. They have strong research and development capabilities, allowing them to develop new products and cater to the needs of both existing and new clients. One of the significant areas of growth for Shaily is in the production of insulin pens, a high-entry barrier segment with low competitive intensity. As the demand for GLP-1 drugs for diabetes and obesity treatment continues to rise, the company is strategically increasing its capacity in this area.
In addition to the healthcare segment, Shaily also operates in the consumer and industrial segments, with the former expected to grow at a high single-digit rate. However, the healthcare and industrial segments are likely to exhibit growth rates of over 20% in the near term.
Overall, Shaily Engineering appears to be well-positioned for future growth, thanks to its focus on innovation, strong customer relationships, and strategic expansion into high-growth segments. With a target price of ₹1,600, investors may want to consider accumulating shares of Shaily Engineering as they look poised for sustained growth in the coming years.
